Vir Biotechnology, Inc. (NASDAQ: VIR) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT VIR BIOTECHNOLOGY, INC.

Vir Biotechnology, Inc. (NASDAQ: VIR)
Listen to this Section

$8.73
-0.0150 ( -0.17% ) 1.1M

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Clinical Trial Pipeline Stages

Drug Name Stage
Sotrovimab VIR-7831 (GSK4182136)DetailsCOVID-19, Infectious disease Failed
VIR-3434 + VIR-2218DetailsInfectious disease, Hepatitis B Phase 2
VIR-3434 + VIR-2218DetailsInfectious disease, Hepatitis Delta Virus Phase 2
VIR-2482 (Universal prophylaxis)DetailsInfluenza, Infectious disease Phase 2
VIR-1388 (HVTN 142)DetailsVaccine, Infectious disease, Human immunodeficiency virus Phase 1
VIR-1111DetailsInfectious disease, Human immunodeficiency virus, Vaccine Failed
Tobevibart + ElebsiranDetailsInfectious disease, Hepatitis Delta Virus Phase 3
VIR-5818 + PembrolizumabDetailsCancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer Phase 1
VIR-5500DetailsCancer, Castration-resistant prostate cancer Phase 1
VIR-1388 (HVTN 142)DetailsInfectious disease, Human immunodeficiency virus, Vaccine Phase 1
VIR-5525DetailsCancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer Phase 1

Market Data
Open $8.73
Previous Close $8.74
Volume 1.1M
Market Cap $1.47B
Day Range $8.57 - $9.03
52 Week Range $4.16 - $11.66
Shares Outstanding 168.65M
Change % -0.17%
Net Change ▼ -0.0150
Insider Ownership -0.07%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology
IPO Year2019
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -5,871,365.00

Date Type Amount Purchased Purchaser
2024-07-16 Sale -75000.00 Eisner Mark
2024-06-12 Sale -4000.00 Ramasastry Saira
2024-06-12 Sale -53118.00 De Backer Marianne
2024-06-03 Sale -8000.00 SCANGOS GEORGE A
2024-06-03 Sale -8000.00 Sigal Charles Elliott
2024-06-03 Sale -8000.00 SATO VICKI L
2024-06-03 Sale -8000.00 Ramasastry Saira
2024-06-03 Sale -8000.00 Hatfield Jeffrey S.
2024-06-03 Sale -8000.00 MORE ROBERT J
2024-06-03 Sale -8000.00 Napolitano Janet

SEC Filings

Form Type Description Pages Date
4 Insider transactions 3 Jun 02, 2025

Latest News

About US

Services

Stay Connected

× Before browsing our site, please accept our cookies policy